PCN198 Access Status of Oncology Medicines Depending on Genetic Profiling in Turkey

Abstract

Efforts to develop new oncology treatments have gained momentum for personalized treatment perspective in terms of genetic profiling. New personalized therapies developed in recent years achieve success in defeating cancer. This study aims to identify the patient access status of oncology medicines for personalized medicine with genetic profiling in Turkey. The information about the oncology medicines depending on genetic profiling was obtained from the FDA & EMA`s official site. The data on the license status, access, and reimbursement coverage of the identified drugs in Turkey are obtained from the List of Licensed Products published by the Turkish Pharmaceutical and Medical Device Agency and Health Implementation Communiqué published by the Social Security Institution. As a result of the analyzes, 66 oncology personalized medicine approved by the FDA or EMA for personalized oncology medicines depending on gene profiling were determined. The medicines identified for 25 different genes which are distributed as 30.3% -lung cancer, 21.2% -e leukemia, 16.6% - breast cancer, 13.6% - melanoma and the rest are kidney, colon, ovarian, prostate, bladder, thyroid, colon and liver cancers indicated, It was analyzed that 59% and 40.9% of the FDA or EMA approved personalized oncology medicines are licensed and not-licensed in Turkey, respectively. 81% of not-licensed are not under reimbursement coverage. However, 77% of licensed personalized oncology medicines are under reimbursement coverage. The average reimbursement coverage of all 66 personalized medicine is calculated as 51%. Depending on the analysis, it is seen that the Social Security Institution (SGK) which is the reimbursement authority of Turkey covers the majority of personalized oncology medicines with the license.